<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570969</url>
  </required_header>
  <id_info>
    <org_study_id>VINMEC LT DON</org_study_id>
    <nct_id>NCT04570969</nct_id>
  </id_info>
  <brief_title>Benefit of ESP Peri Operative Analgesia for Live Liver Donor Transplantation</brief_title>
  <acronym>ESPLIVERDON</acronym>
  <official_title>Improvement of Quality of Life After Live Liver Donation by ESP Peri Operative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver donors have a significant risk to develop persistent and chronic pain around 20 to 30%&#xD;
      affecting social and professional life (17%) up to 1 year after the surgery.&#xD;
&#xD;
      To donate a part of liver is a beautiful gift reason why the pain relief must be improved.&#xD;
&#xD;
      Meta-analysis showed that the best prevention against post operative chronic pain are the&#xD;
      techniques blocking the pain signal (regional anaesthesia) Patients after liver donation are&#xD;
      still in pain even in 2020 with the best multimodal analgesia medications.&#xD;
&#xD;
      Erector sinae Plane Block (ESP) ESP will block the signal and improve the pain relief we hope&#xD;
      to demonstrate that it will reduce the risk to develop post operative chronic pain and&#xD;
      improve the quality of recovery and the quality of life after liver donation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Goals:&#xD;
&#xD;
           Compare quality of pain relief and quality of life between bilateral ESP bilateral&#xD;
           catheters Vs Opioid analgesia in donor patients for liver donation.&#xD;
&#xD;
        2. Methodology:&#xD;
&#xD;
           • Selection criteria: Age &gt; 18 years old Be volunteer to donate liver Agree to&#xD;
           participate in the trial&#xD;
&#xD;
           • Exclusion criteria: Use of chronic opioids Contra-indication tom perform ESP catheter&#xD;
           (Infection near puncture point, Severe thoracic scoliosis, allergie to local&#xD;
           anesthestics) A diagnosis of a chronic pain conditionDepression or other psychiatric&#xD;
           diagnosis&#xD;
&#xD;
           • Study design: Prospective Randomized Controlled Trial.&#xD;
&#xD;
           Patients who agree to join the study will be randomized into 2 groups:&#xD;
&#xD;
           Group 1 (Control group): standard of care in liver donation : Intraoperative analgesia&#xD;
           by Opioid sufentanil and post operative analgesia by PCA opioid morphine Group 2&#xD;
           (treatement group): Standard peri-operative analgesia for liver donation in since&#xD;
           Investigators use regional anaesthesia as first line treatement for peri operative&#xD;
           analgesia Bilateral ESP catheters with continuous regional analgesia by infusion of&#xD;
           local anesthestic (Ropivacaine)&#xD;
&#xD;
           Sample size: investigators expected to increase the Quality of LIfe (QoL) score (using&#xD;
           under-the-curve area) from 36·9 for the ERAS group to 38.3 for ESP group The sample size&#xD;
           of 10 patients per group is required to detect such changes assuming a confidence&#xD;
           interval of 95% with a power of 90% and alpha = 0.05. Considering 20% of drop-out, the&#xD;
           total sample size is 24 patients (12 patients each group)&#xD;
&#xD;
        3. Project outcomes:&#xD;
&#xD;
             -  Primary outcomes Quality of pain relief with opioid consumption&#xD;
&#xD;
             -  Secondary outcomes Duration of hospitalisation participants satisfaction Quality of&#xD;
                recovery (QOR 16) Pain at 1 &amp; 3 months rest and mobilization + QOL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled prospective trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of pain relief at rest</measure>
    <time_frame>from day 0 = day of surgery to day 180</time_frame>
    <description>Visual analgesic score at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quality of pain relief at mouvement</measure>
    <time_frame>from day 0 = day of surgery to day 180</time_frame>
    <description>Visual analgesic score at mouvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>from day 0 to 30 days after the day of surgery</time_frame>
    <description>Total dose of opioids required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>From day = 0 day of the surgery to day to discharge day 15 maximum</time_frame>
    <description>Duration of hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Score based on Table quality of recovery including 15 criteria from 0 to 10 each ) = poor 10 = excellent poor recovery scale 0 to 150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1 month after the surgery</time_frame>
    <description>index from 0 not satisfy to 10 extremely satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) after donation</measure>
    <time_frame>1 months and 3 months after surgery</time_frame>
    <description>The Form QOL (36) is a 36-item, patient-reported survey of patient health and mesure the surgical outcomes. The SF-36 is a measure of health status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Liver Transplant Disorder</condition>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Peri-operative analgesia by opioids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri operative regional analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector spinae plane block</intervention_name>
    <description>Insertion of bilateral catheters in the intersfacia space of erector spinae muscle</description>
    <arm_group_label>Peri operative regional analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age more than 18 and less than 61&#xD;
&#xD;
          -  Be volunteer to donate liver&#xD;
&#xD;
          -  agree to participate to study and consent signed&#xD;
&#xD;
          -  Risk of americain society of anesthesiologists score ASA from 1 to 5 score ASA must be&#xD;
             1 only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of chronic opioid before the surgery&#xD;
&#xD;
          -  A diagnosis of chronic pain condition&#xD;
&#xD;
          -  Contra indication to perform ESP catheter&#xD;
&#xD;
          -  allergy to local anesthestics&#xD;
&#xD;
          -  Depression or psychiatric diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VinMec INternational hospital</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Macaire, MD</last_name>
      <phone>0966103845</phone>
      <email>ph.macaire@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vinmec Healthcare System</investigator_affiliation>
    <investigator_full_name>Philippe Macaire</investigator_full_name>
    <investigator_title>Director of anesthesia and pain management - Anesthesiologist MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

